| 2023/09/29 17:35:20 | |
|---|---|
| Price | |
| 77.54 EUR | |
| Difference | -0.46% (-0.36) |
General attributes
| ISIN | BE0003739530 |
| Symbol | UCB |
| Exchange | Euronext Brussels |
| Currency | EUR |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 14,711 EUR |
| Benchmark | BEL 20 INDEX |
Market data
| Bid (Bid size) | 77.50 EUR (48) |
| Ask (Ask size) | 78.34 EUR (30) |
| Open | 78.36 EUR |
| High | 78.70 EUR |
| Low | 77.54 EUR |
| Close (prev. day) | 77.90 EUR |
| VWAP | 77.650511 EUR |
| Volume (pcs) | 331,388 |
| Trading volume | 25,732,448.00 |
| Number of trades | 1,847 |
| Last size | 30 |
Futures and Options
| Related Futures | 23 |
| Related Options | - |
PDF Downloads
| Company report: UCB S.A. |  |
Scale: ABS REL
Instrument
Add Benchmark:
Information about previous performance does not guarantee future performance.Source: FactSet
Recent research
| Date | Headline | Download | |
| 2023/09/29 |
|
Global Equity Ratings |
|
| 2023/09/08 |
|
Global Equity Ratings |
|
| 2023/08/22 |
|
Global Equity Ratings |
|
| 2023/08/17 |
|
Global Equity Ratings |
|
| 2023/08/09 |
|
Global Equity Ratings |
|
| 2023/09/29 17:35:20 | |
|---|---|
| Price | |
| 77.54 EUR | |
| Difference | -0.46% (-0.36) |
General attributes
| ISIN | BE0003739530 |
| Symbol | UCB |
| Exchange | Euronext Brussels |
| Currency | EUR |
| Sector | Chemical / Pharmaceutical / Health |
| Security type | Stock |
| Market cap (m) | 14,711 EUR |
| Benchmark | BEL 20 INDEX |
Market data
| Bid (Bid size) | 77.50 EUR (48) |
| Ask (Ask size) | 78.34 EUR (30) |
| Open | 78.36 EUR |
| High | 78.70 EUR |
| Low | 77.54 EUR |
| Close (prev. day) | 77.90 EUR |
| VWAP | 77.650511 EUR |
| Volume (pcs) | 331,388 |
| Trading volume | 25,732,448.00 |
| Number of trades | 1,847 |
| Last size | 30 |
Performance and Risk
| 6m | 1Y | 3Y | |
| Perf (%) | -6.49% | +9.03% | -20.59% |
| Perf (abs.) | -5.38 | +6.42 | -20.10 |
| Beta | 0.81 | 0.74 | 0.59 |
| Volatility | 21.11 | 23.79 | 24.83 |
Scale: ABS REL
Instrument
Add Benchmark:
Information about previous performance does not guarantee future performance.Source: FactSet
Price data
| Ø price 5 days | Ø volume 5 days (pcs.) | 78.79 EUR (269,053) |
| Ø price 30 days | Ø volume 30 days (pcs.) | 81.82 EUR (195,307) |
| Ø price 100 days | Ø volume 100 days (pcs.) | 82.00 EUR (189,059) |
| Ø price 250 days | Ø volume 250 days (pcs.) | 79.72 EUR (235,176) |
| YTD High | date | 88.80 EUR (2023/05/19) |
| YTD Low | date | 72.84 EUR (2023/02/02) |
| 52 Weeks High | date | 88.80 EUR (2023/05/19) |
| 52 Weeks Low | date | 69.56 EUR (2022/10/03) |
All listings for UCB S.A.
| Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
| Vienna Stock Exchange | 2023/09/28 | 09:05 | 78.46 EUR | 0.00 | 3 |
| Tradegate | 2023/09/29 | 22:26 | 77.80 EUR | 0.04 | 5 |
| Stuttgart | 2023/09/29 | 19:37 | 77.64 EUR | 0.00 | 7 |
| Munich | 2023/09/29 | 08:00 | 77.90 EUR | 0.00 | 1 |
| London Stock Exchange European Trade Reporting | 2023/09/29 | 17:30 | 77.93 EUR | 0.00 | 1 |
| Frankfurt | 2023/09/29 | 08:05 | 78.02 EUR | 0.00 | 1 |
| FINRA other OTC Issues | 2023/09/20 | 19:36 | 89.52 USD | 0.09 | 2 |
| Euronext Brussels | 2023/09/29 | 17:35 | 77.54 EUR | 25.73 | 1,847 |
| Duesseldorf | 2023/09/29 | 19:30 | 77.40 EUR | 0.00 | 5 |
| Berlin | 2023/09/29 | 08:06 | 77.98 EUR | 0.00 | 1 |
| BX Swiss | 2023/06/21 | 18:00 | 83.003 CHF | 0.02 | 1 |
Company Logo
Contact Details
| UCB SA |
| - - |
| Allée de la Recherche, 60 - 1070 Brüssel |
| Telefon: +32-2-559-99-99 |
| Fax: +32-2-559-99-00 |
| E-mail: contactucb@ucb.com |
PDF Downloads
| Company report: UCB S.A. | |
Company Profile
UCB SA engages in the research and development biopharmaceuticals products. It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec. The company was founded by Emmanuel Janssen on January 18, 1928 and is headquartered in Brussels, Belgium. |
Members of Management Board
| Jean-Christophe Tellier | Chairman of Managing Board |
| Bill Silbey | Member of Executive Committee |
| Charl van Zyl | Member of Executive Committee |
| Dhaval Patel | Member of Executive Committee |
| Emmanuel Caeymaex | Member of Executive Committee |
| Iris Löw-Friedrich | Member of Executive Committee |
| Jean Luc Fleurial | Member of Executive Committee |
| Kirsten Lund-Jurgensen | Member of Executive Committee |
| Sandrine Dufour | Member of Executive Committee |
Board of directors
| Jonathan Peacock | Chairman of Supervisory Board |
| Dame Davies | Member of Supervisory Board |
| Jan Berger | Member of Supervisory Board |
| Susan Gasser | Member of Supervisory Board |
| Albrecht de Graeve | Member of Supervisory Board |
| Charles-Antoine Janssen | Member of Supervisory Board |
| Cyril Janssen | Member of Supervisory Board |
| Fiona du Monceau-de Hemptinne | Member of Supervisory Board |
| Jonkheer Cédric van Rijckevorsel | Member of Supervisory Board |
| Maëlys Castella | Member of Supervisory Board |
| Pierre Gurdjian | Member of Supervisory Board |
| Ulf Arne Wiinberg | Member of Supervisory Board |